Acute myeloid leukemia

New England Journal of Medicine

Volumn 373, Issue 12, 2015, Pages 1136-1152

  Döhner, Hartmut ^a   Weisdorf, Daniel J ^b   Bloomfield, Clara D ^c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF MINNESOTA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; GENOMICS; GRAFT REJECTION; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MULTIMODALITY CANCER THERAPY; MUTATION; PROGNOSIS; REMISSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTARABINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 84942043924     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1406184     Document Type: Review

References (77)

1. Dö hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
2. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.
3. Grö schel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014; 157: 369-81.
4. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469-75.
5. Gaidzik VI,Bullinger L,Schlenk RF,et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group J Clin Oncol 2011 29 1364-72.
6. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 2012; 30: 3109-18.
7. Nacheva EP, G race CD, Brazma D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 2013; 161: 541-50.
8. Godley LA. Inherited predisposition to acute myeloid leukemia. Semin Hematol 2014; 51: 306-21.
9. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015; 27: 658-70.
10. . Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 2015; 47: 180-5.
11. The Cancer Genome Atlas Research Netw ork. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
12. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-10.
13. Krö nke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122: 100-8.
14. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-33.
15. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014; 111: 2548-53.
16. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-81.
17. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-98.
18. Genovese G, Kä hler AK, Handsaker RE, et al. Clonal hematopoiesis and bloodcancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-87.
19. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125: 1367-76.
20. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense ' induction regimens: a report from SWOG and MD Anderson. Leukemia 2014; 28: 289-92.
21. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-86.
22. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol 2014; 15(9): e382-e394.
23. Walter RB, Othus M, Paietta EM, et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 2015 March 16 (Epub ahead of print).
24. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for " prime time" ? Blood 2014; 124: 3345-55.
25. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015; 125: 3878-85.
26. Hills RK,Castaigne S,Appelbaum FR,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a metaanalysis of individual patient data from randomised controlled trials Lancet Oncol 2014, 15, 986-96.
27. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-Age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249-56.
28. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664-71.
29. Gupta V, Ta llman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011; 117: 2307-18.
30. Lö wenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013; 121: 26-8.
31. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica 2014; 99: 1663-70.
32. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360-8.
33. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037-42.
34. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and metaanalysis of prospective clinical trials. JAMA 2009; 301: 2349-61.
35. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-wellmatched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytog enetics at diagnosis. Blood 2010; 116: 1839-48.
36. Litzow MR, Tarima S, P érez WS, et al. Allogeneic transplantation for therapyrelated myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850-7.
37. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leu kemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-87.
38. Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic ce ll transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17: 1796-803.
39. Bornhä user M, Kienast J, Trensche l R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035-44.
40. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371: 339-48.
41. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12: 1214-21.
42. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4 693-9.
43. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012; 119: 1972-80.
44. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310-6.
45. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stra tified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024-31.
46. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-96.
47. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-101.
48. Pasquini MC,Devine S,Mendizabal A,et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation J Clin Oncol 2012 30, 3194-201.
49. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813-21.
50. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transp lantation. III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant 2014; 20: 4-13.
51. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with l ow-dose azacitidine after allogeneic hematopoietic stem cell transplantation for relapsed AML or MDS: a dose and schedule finding study. Cancer 2010; 116: 5420-31.
52. Takahashi Y, Vagge S, Agostinelli S , et al. Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: a global health initiative by the International Consortium of Total Marrow Irradiation. Int J Radiat O ncol Biol Phys 2015; 91: 30-8.
53. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence fo r a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402-12.
54. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor killer cell Ig-like receptor B haplo types, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 2014; 192: 4592-600.
55. Di Stasi A, Jimenez AM, Minagawa K , Al-Obaidi M, Rezvani K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015; 6: 36.
56. Hills RK, Burnett AK. Applicability of a " Pick a Winner" trial design to acute myeloid leukemia. Blood 2011; 118: 2389-94.
57. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, openlabel, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-7.
58. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30 % blasts. Blood 2015; 126: 291-9.
59. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126: 319-27.
60. Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 2015 August 18 (Epub ahead of print).
61. Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 2014; 124: 115. abstract.
62. Dombret H, Preudhomme C, Berthon C, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. Blood 2014; 124: 117. abstract.
63. Rö llig C, Müller-Tidow C, Hüttmann A, et al. Sorafenib versus placebo in additio n to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Blood 2014; 124: 6. abstract.
64. Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective antileukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013; 161: 117-27.
65. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia . Blood 2013; 121: 4854-60.
66. Ravandi F, Ritchie E, Sayar H, et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plu s cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR). Blood 2014; 124: LBA-6. abstract.
67. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014; 123: 3239-46.
68. DiNardo CD, Cortes JE. New t reatment for acute myelogenous leukemia. Expert Opin Pharmacother 2015; 16: 95-106.
69. Wander SA,Levis MJ,Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond Ther Adv Hematol 2014, 5, 65-77.
70. Dawson MA, Kouzarides T, Huntly BJP. Targeting epigenetic readers in cancer. N Engl J Med 2012; 367: 647-57.
71. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013; 121: 3563-72.
72. Gasiorowski RE, Clark GJ, Bradstock K, Hart DNJ. Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014; 164: 481-95.
73. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-6.
74. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015; 21: 178-84.
75. Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013; 121: 4166-74.
76. Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014; 123: 2343-54.
77. Lynn RC, Poussin M, Kalota A, et al. Targeting of folate receptor ? on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 2015; 125: 3466-76.